Manchao Zhang

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi LIGHT sensitizes IFN-gamma-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways
    Man Chao Zhang
    Division of Hematology Oncology, Department of Internal Medicine, The University of Michigan, Ann Arbor, MI 48109 0934, USA
    Cell Res 14:117-24. 2004
  2. ncbi Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells
    Manchao Zhang
    Lombardi Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
    Biochem Pharmacol 66:93-103. 2003
  3. ncbi LIGHT sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members
    Manchao Zhang
    Structure Biology and Cancer Drug Discovery Program, Lombardi Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Lett 195:201-10. 2003
  4. ncbi Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
    Zaneta Nikolovska-Coleska
    University of Michigan Comprehensive Cancer Center, Departments of Internal Medicine and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109 0934, USA
    J Med Chem 47:2430-40. 2004
  5. pmc Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics
    Lori W Lee
    Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
    Bioorg Med Chem Lett 19:6233-6. 2009
  6. ncbi Light stimulates IFNgamma-mediated intercellular adhesion molecule-1 upregulation of cancer cells
    Manchao Zhang
    Structure Biology and Cancer Drug Discovery Program, Lombardi Cancer Center and Department of Oncology, Washington, DC, USA
    Hum Immunol 64:416-26. 2003
  7. pmc Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer
    LiWei Bao
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 69:5829-34. 2009
  8. ncbi Differential growth inhibition and induction of apoptosis by gossypol between HCT116 and HCT116/Bax(-/-) colorectal cancer cells
    Manchao Zhang
    Department of Biochemistry and Molecular Pharmacology and Mary Babb Rodalph Cancer Center, West Virginia University, Morgantown, West Virginia 26506 9142, USA
    Clin Exp Pharmacol Physiol 34:230-7. 2007
  9. ncbi Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells
    Manchao Zhang
    Department of Biochemistry and Molecular Pharmacology, West Virginia University, 1 Medical Center Drive, Morgantown, WV 26506 9142, USA
    Cancer Lett 252:244-58. 2007
  10. ncbi Subcellular localization of caspase-3 activation correlates with changes in apoptotic morphology in MOLT-4 leukemia cells exposed to X-ray irradiation
    Yongdong Feng
    Tongji Cancer Institute, Department of Surgery, Tongji Hospital, Tongji Medical College, Central China University of Science and Technology, Wuhan, Hubei 430030, P R China
    Int J Oncol 27:699-704. 2005

Collaborators

  • Quintin Pan
  • Shaomeng Wang
  • Renxiao Wang
  • Peng Li
  • Marc E Lippman
  • Hong Ding
  • H Riedel
  • Toshiyuki Araki
  • R M Mohammad
  • Dajun Yang
  • Zhen Dan Shi
  • Terrence R Burke
  • Kyeong Lee
  • Karen M Worthy
  • Robert J Fisher
  • Hongpeng Liu
  • Yongdong Feng
  • Chang Qing Wei
  • Lori W Lee
  • Anna K Mapp
  • LiWei Bao
  • Jianping Gong
  • Jianhong Wu
  • Chunzhao Yu
  • Junbo Hu
  • Eddie Reed
  • Qingdi Q Li
  • Deding Tao
  • Jichao Qin
  • Sang Uk Kang
  • Zaneta Nikolovska-Coleska
  • Ribo Guo
  • Lindsey R Roberts
  • Christopher E C Taylor
  • Michael A Gorin
  • Theodoros N Teknos
  • Jean Paul Desaulniers
  • Alejandra C Ventura
  • William C Pomerantz
  • Sofia D Merajver
  • Jonas W Højfeldt
  • Jinshun Zhao
  • Xiping Li
  • Lakshman Bindu
  • Daxin Xie
  • Gangduo Wang
  • Yisheng Zhong
  • Xiaolan Li
  • Yunfeng Zhu
  • Wei Xiao
  • Lakshman K Bindu
  • Shuangyou Liu
  • Yuping Song
  • York Tomita
  • James A Kelley
  • Peter P Roller
  • Zengjian Hu
  • Liang Xu
  • Benjamin G Neel
  • Xueliang Fang
  • Matthew J Fivash
  • Yang Gao
  • Bihua Li

Detail Information

Publications26

  1. ncbi LIGHT sensitizes IFN-gamma-mediated apoptosis of HT-29 human carcinoma cells through both death receptor and mitochondria pathways
    Man Chao Zhang
    Division of Hematology Oncology, Department of Internal Medicine, The University of Michigan, Ann Arbor, MI 48109 0934, USA
    Cell Res 14:117-24. 2004
    ..These results suggest that LIGHT-induced, IFNg-mediated apoptosis of HT-29 cells is caspase-dependent, and LIGHT signaling is mediated through both death receptor and mitochondria pathways...
  2. ncbi Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells
    Manchao Zhang
    Lombardi Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
    Biochem Pharmacol 66:93-103. 2003
    ..Gossypol-induced apoptosis of HT-29 cells is through first the mitochondrial pathway, then the death receptor pathway, and the mitochondria pathway is, at least in part, involved in cyto-c release...
  3. ncbi LIGHT sensitizes IFNgamma-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members
    Manchao Zhang
    Structure Biology and Cancer Drug Discovery Program, Lombardi Cancer Center and Department of Oncology, Georgetown University Medical Center, Washington, DC 20007, USA
    Cancer Lett 195:201-10. 2003
    ....
  4. ncbi Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database
    Zaneta Nikolovska-Coleska
    University of Michigan Comprehensive Cancer Center, Departments of Internal Medicine and Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109 0934, USA
    J Med Chem 47:2430-40. 2004
    ....
  5. pmc Inhibition of ErbB2(Her2) expression with small molecule transcription factor mimics
    Lori W Lee
    Department of Chemistry, University of Michigan, Ann Arbor, MI 48109, USA
    Bioorg Med Chem Lett 19:6233-6. 2009
    ..Addition of the small molecules leads to decreased expression of the cell surface growth receptor ErbB2(Her2) in ErbB2-positive cancer cells and, correspondingly, decreased proliferation...
  6. ncbi Light stimulates IFNgamma-mediated intercellular adhesion molecule-1 upregulation of cancer cells
    Manchao Zhang
    Structure Biology and Cancer Drug Discovery Program, Lombardi Cancer Center and Department of Oncology, Washington, DC, USA
    Hum Immunol 64:416-26. 2003
    ..These findings suggest that LIGHT-induced inhibition of tumor growth is highly correlated with its upregulation of ICAM-1 expression...
  7. pmc Preclinical development of a bifunctional cancer cell homing, PKCepsilon inhibitory peptide for the treatment of head and neck cancer
    LiWei Bao
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Cancer Res 69:5829-34. 2009
    ..02) retards the growth of UMSCC1 xenografts in nude mice. Our work indicates that the bifunctional HN1-PKCepsilon inhibitory peptide represents a promising novel therapeutic strategy for HNSCC...
  8. ncbi Differential growth inhibition and induction of apoptosis by gossypol between HCT116 and HCT116/Bax(-/-) colorectal cancer cells
    Manchao Zhang
    Department of Biochemistry and Molecular Pharmacology and Mary Babb Rodalph Cancer Center, West Virginia University, Morgantown, West Virginia 26506 9142, USA
    Clin Exp Pharmacol Physiol 34:230-7. 2007
    ..3. These findings suggest that the contribution of Bax to gossypol-induced growth inhibition and apoptosis is dose dependent and that gossypol-induced apoptosis requires activation of caspase 3, 8, and 9...
  9. ncbi Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells
    Manchao Zhang
    Department of Biochemistry and Molecular Pharmacology, West Virginia University, 1 Medical Center Drive, Morgantown, WV 26506 9142, USA
    Cancer Lett 252:244-58. 2007
    ..CMEP inhibits growth and induces apoptosis in cancer cells which have high-levels of AKT activation and lack PTEN or harbor PTEN mutation...
  10. ncbi Subcellular localization of caspase-3 activation correlates with changes in apoptotic morphology in MOLT-4 leukemia cells exposed to X-ray irradiation
    Yongdong Feng
    Tongji Cancer Institute, Department of Surgery, Tongji Hospital, Tongji Medical College, Central China University of Science and Technology, Wuhan, Hubei 430030, P R China
    Int J Oncol 27:699-704. 2005
    ..The spatial shift of activated caspase-3 in X-ray-induced apoptotic MOLT-4 leukemia cells is a process of crucial importance for apoptosis...
  11. ncbi Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands
    Zhen Dan Shi
    Laboratory of Medicinal Chemistry, CCR, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    J Med Chem 47:2166-9. 2004
    ..In extracellular assays affinity was enhanced approximately 5-fold relative to an open-chain congener. Enhancement was also observed in whole-cell assays examining blockade of Grb2 binding to the erbB-2 protein-tyrosine kinase...
  12. ncbi A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity
    Zhen Dan Shi
    Laboratory of Medicinal Chemistry, CCR, NCI, NIH, Frederick, MD 21702 1201, USA
    Biochem Biophys Res Commun 310:378-83. 2003
    ..6 microM). Macrocycle 5 may be representative of a new class of therapeutically relevant Grb2 SH2 domain-directed agents...
  13. ncbi Concise and enantioselective synthesis of Fmoc-Pmp(But)2-OH and design of potent Pmp-containing Grb2-SH2 domain antagonists
    Peng Li
    Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, USA
    Org Lett 5:3095-8. 2003
    ..With this key building block, we are able to efficiently synthesize a series of potent Pmp-containing Grb2-SH2 domain antagonists, which can be used as chemotherapeutic leads for the treatment of erbB2-overexpressed breast cancer...
  14. ncbi Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspase-dependent and caspase-independent cell death pathways
    Manchao Zhang
    Department of Biochemistry and Molecular Pharmacology, West Virginia University, Morgantown, WV 26506, USA
    Life Sci 80:767-74. 2007
    ....
  15. ncbi A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells
    Manchao Zhang
    Department of Biochemistry, West Virginia University, Morgantown, WV 26506, USA
    Ann Hematol 86:471-81. 2007
    ..MNB prolongs the life spans of HL-60 bearing mice, potently kills fresh AML and ALL cells, indicating that it has the potential to be developed to treat leukemia...
  16. ncbi Essential role of PSM/SH2-B variants in insulin receptor catalytic activation and the resulting cellular responses
    Manchao Zhang
    Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, WV 26506 9142, USA
    J Cell Biochem 103:162-81. 2008
    ..PSM variants act as internal IR ligands that in addition to potentiating the insulin response stimulate IR catalytic activation even in the absence of insulin...
  17. doi PSM/SH2B1 splice variants: critical role in src catalytic activation and the resulting STAT3s-mediated mitogenic response
    Manchao Zhang
    Department of Biochemistry, West Virginia University, School of Medicine, Morgantown, West Virginia 26506 9142, USA
    J Cell Biochem 104:105-18. 2008
    ..Our results implicate an essential role of the PSM variants in the activation of the Src kinase and the resulting mitogenic response--extending to phenotypic cell transformation and involving the established Src substrate STAT3...
  18. ncbi Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP)
    Manchao Zhang
    Department of Biochemistry and Molecular Pharmacology, West Virginia University, 1 Medical Center Drive, Morgantown, WV 26506 9142, United States
    Biochem Pharmacol 73:15-24. 2007
    ..In conclusion, by specific blockade of the activation of AKT, CMEP preferentially inhibits growth and induces apoptosis in prostate cancer cells which have high-levels of AKT activation...
  19. ncbi Differential expression of cyclins A, B1, D3 and E in G1 phase of the cell cycle between the synchronized and asynchronously growing MOLT-4 cells
    Chunzhao Yu
    Center for Cancer Research, and Department of Surgery, Tongji Hospital, Tongji Medical College, Central China University of Science and Technology, Wuhan 430030, PR China
    Int J Mol Med 16:645-51. 2005
    ..Thus, it appears that thymidine-treated, synchronized cells may not be suitable experimental models for the study of normal cell cycle...
  20. ncbi Design and synthesis of 4-(alpha-hydroxymalonyl)phenylalanine as a new phosphotyrosyl mimetic and its use in growth factor receptor bound 2 src-homology 2 (Grb2 SH2) domain-binding peptides
    Sang Uk Kang
    Laboratory of Medicinal Chemistry, CCR, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    J Med Chem 48:5369-72. 2005
    ..These results are consistent with de-esterification and at least partial intracellular decarboxylation...
  21. ncbi Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity
    Zhen Dan Shi
    Laboratory of Medicinal Chemistry, CCR, NCI, NIH, Frederick, MD 21702, USA
    Bioorg Med Chem 13:4200-8. 2005
    ..4 nM, the title macrocycle (5) is among the most potent biotinylated SH2 domain-binding ligands yet disclosed. This should be a useful tool for elucidating physiological targets of certain Grb2 SH2 domain-binding antagonists...
  22. ncbi Structural basis for a non-phosphorus-containing cyclic peptide binding to Grb2-SH2 domain with high affinity
    Peng Li
    Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, 376 Boyles Street, Frederick, MD 21702 1201, USA
    Biochem Biophys Res Commun 307:1038-44. 2003
    ..Whole cell assays indicate that peptide 20 can penetrate the cell membranes and inhibit the association of Grb2 with p185(erbB2) in erbB2-overexpressing MDA-MA-453 cancer cells at low micromolar concentrations...
  23. ncbi Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides
    Kyeong Lee
    Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute, National Institutes of Health, NCI Frederick, P O Box B, Building 376, Boyles Street, Frederick, Maryland 21702, USA
    J Med Chem 46:2621-30. 2003
    ..The resulting cyclic beta-amino peptide is the first of a new class of pTyr-mimetic-containing ligands that may have utility in the development of antagonists of both Grb2 SH2 domains and other pTyr-dependent signaling systems...
  24. ncbi Potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics
    Peng Li
    Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, 21702, Frederick, MD, USA
    Bioorg Med Chem Lett 13:2173-7. 2003
    ..This potent peptidomimetic provides a novel template for the development of non-pTyr containing Grb2-SH2 domain antagonists and acts as a chemotherapeutic lead for the treatment of erbB2-related cancer...
  25. ncbi Structure-based design of thioether-bridged cyclic phosphopeptides binding to Grb2-SH2 domain
    Peng Li
    Laboratory of Medicinal Chemistry, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
    Bioorg Med Chem Lett 13:895-9. 2003
    ..Based upon these global modifications, a highly potent peptide ligand 12 was discovered with an IC(50)=1.68 nM, evaluated by ELISA binding essay. Ligand 12 is at least 10(5) more potent than the lead peptide, termed G1TE...
  26. ncbi Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems
    Chang Qing Wei
    Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
    J Med Chem 46:244-54. 2003
    ..002 microM in an extracellular ELISA-based assay, and in MDA-MB-453 cells, it both inhibited the association of Grb2 with p185(erbB-2) and exhibited antimitogenic effects with submicromolar IC50 values...